The use of biological variables to predict outcome in multiple myeloma

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Blood cancer journal·2024

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Leukemia·2017

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Leukemia·2017

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Blood cancer journal·2017

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.

British journal of haematology·2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

British journal of haematology·2026

Predicted microbiome-associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia.

British journal of haematology·2026

Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft-versus-host disease.

British journal of haematology·2026

Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults.

British journal of haematology·2026

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

British journal of haematology·2026

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

Acta oncologica (Stockholm, Sweden)·2026

Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti-PD-1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Immunology·2026

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

Journal of the National Cancer Institute·2026

Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States.

The oncologist·2026

Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.

Microbiology spectrum·2026

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

Revista espanola de enfermedades digestivas·2026

Related Experiment Videos

The use of biological variables to predict outcome in multiple myeloma

Related Concept Videos

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Predicted microbiome-associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia.

Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft-versus-host disease.

Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults.

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti-PD-1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States.

Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

Related Experiment Videos

The use of biological variables to predict outcome in multiple myeloma

Related Concept Videos

Related Articles